In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prism Pharmaceuticals Inc.

Division of Baxter International Inc.

Latest From Prism Pharmaceuticals Inc.

Venture Affairs Of The Heart

A survey of the fundraising activities of 183 private cardiovascular medtech, biopharma, and diagnostics companies from 2010 through April 2015 revealed that by 2014, following two years of waning venture investments, the group had raised less than half the capital secured in 2010. And although the average raised per round was roughly the same, the volume of deals was significantly higher in 2010.

Medical Device BioPharmaceutical

Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q2 2011

During the second quarter of 2011, 57 medical device companies brought in a total of $1.7 billion in financings. The M&A activity reached $28.8 billion, unusually high due to Johnson & Johnson's $21.7 billion takeover of orthopedic device maker Synthes. VC funding represented $76 million or 43% of the second quarter's in vitro diagnostics/research financing aggregate of $177 million. A hefty $4.1 billion was spent on 11 in vitro diagnostic/research M&A transactions, the largest being Thermo Fisher's $3.5 billion buy of Swedish genetics testing firm Phadia AB.

Medical Device

Baxter makes $380M grab for Baxa to boost IV and oral delivery

Baxter once again plans to add to its IV solutions business – this time through the acquisition Baxa Corporation for $380 million in cash. Baxa is a privately held company that has developed pharmacy devices and software that improves the safety of oral and IV dose preparation and delivery.

Metabolic Disorders Switzerland

Medicines Co gains worldwide licence to Ligand's Captisol-enabled IV clopidogrel

The Medicines Company has licensed worldwide rights to Ligand’s Captisol-enabled intravenous formulation of the top-selling product clopidogrel (Sanofi/Bristol-Myers Squibb's Plavix) for an upfront payment of $1.75 million.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Baxter International Inc.
  • Senior Management
  • Warren D Cooper, Pres. & CEO
  • Contact Info
  • Prism Pharmaceuticals Inc.
    Phone: (610) 265-7710
    1016 W 9th Ave.
    Ste. 130
    King of Prussia, PA 19406